Publications

Featured publications from our laboratory:

Su T, Duran GE, Kwang AC, Ramchurren N, Fling SP, Kim YH, Khodadoust MS. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome. Oncoimmunology 11(1), 2022.

Beygi S, Duran GE, Fernandez-Pol S, Rook AH, Kim YH, Khodadoust MS. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood 139(26): 3732-3736, 2022.

Beygi S, Fernandez-Pol S, Duran GE, Wang EB, Stehr H, Zehnder JL, Ramchurren N, Fling SP, Cheever MA, Weng WK, Kim YH, Khodadoust MS. Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Adv 5(3): 771-774, 2021.

Wang JY, Hirotsu KE, Neal TM, Raghavan SS, Kwong BY, Khodadoust MS, Brown RA, Novoa RA, Kim YH, Rieger KE. Histopathologic characterization of mogamulizumab-associated rash. Am J Surg Pathol 44(12): 2020.

Khodadoust MS, Olsson N, Chen B, Sworder B, Shree T, Liu CL, Zhang L, Czerwinski DK, Davis MM, Levy R, Elias JE, Alizadeh AA. B-cell lymphomas present immunoglobulin neoantigens. Blood 133(8): 878-881, 2019.

Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol 2019.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol 36(28):2845-2853, 2018.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711: 243-259, 2018.

Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543(7647): 723-727, 2017.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M. Early Detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov 7(12): 1394-1403, 2017.

Khodadoust MS, Luo B, Medeiros BC, Johnson RC, Ewalt MD, Schalkwyk AS, Bangs CD, Cherry AM, Arai S, Arber DA, Zehnder JL, Gotlib J. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30(4): 947-50, 2016.

Hiniker SM, Pollom EL, Khodadoust MS, Kozak MM, Xu G, Quon A, Advani RH, Hoppe RT. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys 92(1): 99-106, 2015.

Khodadoust MS, Alizadeh AA. Tumor antigen discovery through translation of the cancer genome. Immunol Res 58(2-3): 292-9, 2014.

Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM, Soengas MS. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 69(16): 6405-13, 2009.